A Phase I Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against BK-Virus in Adult Kidney Transplant Recipients

Publications Category : General Surgery / Surgery, Nephrology

Author(s): Lucy Ptak, Ross O. Meyers, Olga Radko-Ganz, Kimberly A. McDowell, Margaret Jorgenson, Maggie Chilsen, Didier Mandelbrot, Jacques Galipeau, Sandesh Parajuli

Project Description : BK polyomavirus (BKPyV) poses a significant threat to kidney transplant recipients (KTR). Current management primarily involves reducing immunosuppression, which increases the risk of rejection. Cell-based immunotherapy with virus-specific T cells (VST) has emerged as an alternative approach for treating BKPyV in KTRs. Patients were treated with VST therapy and followed for 52 weeks. Safety and tolerability were the primary focus of this trial.